ENDOMYOCARDIAL BIOPSY-BASED DIAGNOSTICS OF INFLAMMATORY CARDIOMYOPATHY - BASELINE ANALYSES OF THE PILOT STUDY
Tématický okruh: Srdeční selhání, transplantace, oběhové podpory | |
Typ: Ústní sdělení - lékařské , Číslo v programu: 447 | |
Sdělení navržené do bloku Asociace/PS/OS: PS Chorob myokardu a perikardu | |
Krejčí J.1, Hude P.2, Špinarová L.1, Ozábalová E.3, Freiberger T.4, Sirotková A.5, Vítovec J.6 1 I. IKAK, LF MU, FNUSA, Brno, 2 I. IKAK, FN u sv. Anny v Brně, Brno, 3 I. IKAK, FNUSA, 4 LF MU, CKTCH, Brno, 5 1. Patologický ústav, FNUSA, Brno, 6 I. IKAK, FN u sv.Anny v Brně, Brno | |
Background: the diagnostics of inflammatory cardiomyopathy (ICM) is nowadays based mainly on the results of endomyocardial biopsy (EMB). Classical histological assessment is insufficient; there is an absolute necessity of imunohistological and genetical evaluation focused on the detection of nucleic acids of potential patogens in endomyocardial biopsy (EMB) specimens. Patients group: there were 30 patients with the symptoms of heart failure lasting less than 12 months and no alternative etiology of heart failure evaluated since December 2009 till Decembre 2010. The mean age was 43 ±13 years, 7 of the patients were women, time since the first symptoms was 2.4 ± 2.1 months. Left ventricle ejection fraction was 23 ± 8 %, NYHA class 2.8 ± 0.5. Conclusion: the role of EMB in the diagnostics of ICM is unsubstitutable. Recent DCM has in 2/3 of our patients group an inflammatory basis. Immunosupresive therapy was limited to 1/3 of the group because of the presence of viral nucleic acid in the myocardium. | |